Krazati Approved for KRASG12C-Mutated Locally Advanced or Metastatic NSCLC

The FDA has approved Krazati (adagrasib) for adults with KRASG12C-mutation locally advanced or metastatic non-small cell lung cancer.

Related Keywords

,Drug Administration ,Mirati Therapeutics Inc ,Agilent Resolution ,